Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

Active, not recruiting

• Conditions: Cushing's Syndrome; Adrenocortical Carcinoma

• Registration Number: NCT00457587
• Lead Sponsor: University of Wuerzburg

Brief Summary

Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09-01
• Study First Submitted: 2007-04-04
• Study First Submitted QC: 2007-04-04
• Study First Posted: 2007-04-06
• Status Verified: 2025-08
• Last Update Submitted: 2025-08-24
• Last Update Posted: 2025-08-26
• Primary Completion: 2027-12
• Study Completion: 2028-12-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• patients with histological proven adrenocortical carcinoma
• healthy persons as control group
• Life expectancy > 6 months

Exclusion Criteria

• autoimmune diseases
• severe clinical condition

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To find reasonable antigens for a vaccination therapy in ACC	day of blood sampling
To investigate the role of tumor-induced suppression in ACC	NA, in vitro study

Trial Locations

Locations (1)

Dept. of Medicine I, University of Wuerzburg; 🇩🇪 Würzburg, Germany